Cronos Group (TSXV:MJN) celebrated the start of the week by accomplishing something none of the other major Canadian licensed producers (LPs) have done so far–earning a listing on the Nasdaq Global Market.

Cronos’ shares will begin trading on the prestigious American exchange on Tuesday (February 27), under the symbol “CRON.” The company announced it will maintain its TSX Venture listing alongside the new Nasdaq option.


“We believe this will increase long-term shareholder value by improving awareness, liquidity, and appeal to institutional investors,” Mike Gorenstein, CEO of Cronos Group said in the company’s announcement.

The public marijuana industry has been on a path of legitimizing itself to generalist investors in order to obtain a wider margin of would-be shareholders. One of the biggest developments in this area was last year’s blockbuster investment deal from Constellation Brands (NYSE:STZ) into Canopy Growth (TSX:WEED) for 9.9 percent equity of Canopy worth $245 million.

Now, Cronos’ entrance into one of the premier exchanges in the world provides a signal of the emergence of the cannabis market.

Cronos CEO wants to create value, not “empire building”

The company currently maintains a “Hold” rating on TipRanks, based on the analyst consensus of Matt Bottomley with Canaccord Genuity, Martin Landry with GMP Capital and Jason Zandberg with PI Financial. Most recently, Bottomley raised the one-year price target for Cronos, while maintaining his “Hold” recommendation.

“With international markets continuing to develop (along with Cronos’ international strategy), we have elected to add incremental value into our SOTP (sum-of-the-parts) analysis to account for Cronos’ increasing international reach,” Bottomley wrote in his note, in which he raised the one year price target for Cronos from $4.15 to $6.

In a recent Ask Me Anything segment on the weed stocks subreddit, Gornstein answered to a question about the approach of the company compared to the rest of the LPs in Canada.

“We’re focused on creating value not empire building,” Gornstein said, adding the company targets the most strategic and highest ROI (return on investment) options for them.

After the markets closed shares of Cronos had seen a 1.13 percent increase to its share price on the TSXV over a year-to-date period, to $9.85. Monday’s announcement resulted in a 10.80 percent rise for Cronos during the trading day.

“Our approach, is that unless there is a strong synergy, if investors want exposure to different verticals we will leave it to them to evaluate and pick their own investments,” Gornstein said.

International aspirations for Cronosworld-hand

This year, Cronos announced the launch of its Australian venture, by creating separate company under its umbrella. Cronos Australia will be led by people selected by the company.

During an investor call Rodney Cocks, CEO, and director of the new Australian venture said the patient population in Australia was expanding thanks to favorable laws and support for these alternative treatments.

Current patients who have access to cannabis treatments must belong in two very specific patient groups: pediatric epilepsy and palliative care patients. A report from 2016 by research firm Deloitte indicated these two groups represented over 30,000 patients.

“I think what we’ve seen in the market is an increased rate of voices and momentum around medicinal cannabis access for patients beyond those two patient groups,” Cocks said during the investor call.

Cronos also holds interests in Israel, via a similar separate venture. In Germany, the company has a partnership that gives it access to 12,000 pharmacies with manufacturer and supplier Pohl-Boskamp.

Investor Takeaway

Cannabis investors have been waiting patiently when the companies in this space move into the most established exchanges available. A wide variety of Canadian producers list on the popular OTC Best Markets as well, but on the Nasdaq, Cronos will find a wider range of investors.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Editor’s Note: This story was updated to reflect the final percentage and price changes for Cronos once the markets closed on Monday

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less